Profile
| Metric | Value |
|---|---|
| Full Name | Natera, Inc. |
| Ticker | NASDAQ: NTRA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | natera.com |
| Employees | 4,424 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $239.56 | |
| Price, 1D Change | -5.83% | |
| Market Cap | $33B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.18 | |
| Revenue | $2B | |
| Revenue, 1Y Change | +56.75% | |
| EPS | -$1.53 | |
| EPS, 1Y Change | +59.62% |
Chart
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$1.53 | |
| EPS Estimate | -$2.47 | |
| EPS Est. Change | -61.47% | |
| Revenue | $1.70B | |
| Revenue Estimate | $2.22B | |
| Revenue Est. Change | +30.71% | |
| Current Price | $239.56 | |
| Price Target | - | $260.00 |
| Price Tgt. Change | - | +8.53% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$3.86 | -$3.78 | +2.05% | |
| -$1.55 | -$1.53 | +1.51% | |
| -$2.47 | N/A | -61.47% | |
| -$2.05 | N/A | -34.29% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.06B | $1.08B | +2.61% | |
| $1.63B | $1.70B | +3.98% | |
| $2.22B | N/A | +30.71% | |
| $2.59B | N/A | +52.91% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +35.64% | |
| Price, 3Y | +548.69% | |
| Market Cap, 1Y | +42.60% | |
| Market Cap, 3Y | +713.08% | |
| Revenue, 1Y | +56.75% | |
| Revenue, 3Y | +171.29% | |
| EPS, 1Y | +59.62% | |
| EPS, 3Y | +70.69% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $239.56 | |
| SMA 200 | $175.42 | |
| SMA 200 vs Price | -26.78% | |
| SMA 50 | $223.69 | |
| SMA 50 vs Price | -6.63% | |
| Beta | 1.18 | |
| ATR | $7.60 | |
| 14-Day RSI | 56.25 | |
| 10-Day Volatility | 46.64% | |
| 1-Year Volatility | 41.29% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $1.70B | |
| EPS | -$1.53 | |
| Gross Profit | $1.02B | |
| Gross Margin | 60.30% | |
| Operating Profit | -$222.29M | |
| Operating Margin | -52.80% | |
| Net Income | -$190.43M | |
| Net Margin | -11.22% | |
| EBITDA | -$191.33M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.16 | |
| Current Ratio | 4.00 | |
| Quick Ratio | 3.87 | |
| - | ||
| F-Score | 5 | |
| Altman Z-Score | 40.00 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 15.78 | |
| PB Ratio | 26.68 | |
| EV/EBITDA | -103.48 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.20B | |
| Cash & Equivalents | $968.28M | |
| Total Assets | $1.69B | |
| Current Assets | $1.38B | |
| Total Liabilities | $490.98M | |
| Current Liabilities | $344.05M | |
| Total Debt | $187.12M | |
| Short Term Debt | $90.53M | |
| Accounts Payable | $34.92M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $1.89B | |
| Operating Expenses | $1.25B | |
| Cost Of Goods Sold | $673.75M | |
| SG&A | $0.00 | |
| D&A | $30.97M | |
| Interest Expense | $0.00 | |
| Income Tax | $695.00K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $135.66M | |
| CFI | $137.62M | |
| CFF | $30.20M | |
| Capex | $76.92M | |
| Free Cash Flow | $58.75M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Guggenheim | → | |
| Canaccord Genuity | → | |
| Wells Fargo | → | |
| JP Morgan | → | |
| Barclays | → | |
| Canaccord Genuity | → | |
| BTIG | → | |
| Morgan Stanley | → | |
| JP Morgan | → | |
| UBS | → |
Analyst sentiment
Institutional ownership
Screeners with NTRA
Data Sources & References
- NTRA Official Website www.natera.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1604821/000110465925107976/0001104659-25-107976-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1604821/000155837025001869/0001558370-25-001869-index.htm
- NTRA Profile on Yahoo Finance finance.yahoo.com/quote/NTRA
- NTRA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/ntra
FAQ
What is the ticker symbol for Natera, Inc.?
The ticker symbol for Natera, Inc. is NASDAQ:NTRA
Does Natera, Inc. pay dividends?
No, Natera, Inc. does not pay dividends
What sector is Natera, Inc. in?
Natera, Inc. is in the Healthcare sector
What industry is Natera, Inc. in?
Natera, Inc. is in the Diagnostics & Research industry
What country is Natera, Inc. based in?
Natera, Inc. is headquartered in United States
When did Natera, Inc. go public?
Natera, Inc. initial public offering (IPO) was on July 1, 2015
Is Natera, Inc. in the S&P 500?
No, Natera, Inc. is not included in the S&P 500 index
Is Natera, Inc. in the NASDAQ 100?
No, Natera, Inc. is not included in the NASDAQ 100 index
Is Natera, Inc. in the Dow Jones?
No, Natera, Inc. is not included in the Dow Jones index
When was Natera, Inc. last earnings report?
Natera, Inc.'s most recent earnings report was on November 6, 2025
When does Natera, Inc. report earnings?
The next expected earnings date for Natera, Inc. is February 26, 2026
